MESO Q3 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+867.3% YoY

Gross Profit

-$10M-82.0% margin

Operating Income

-$16M-128.5% margin

Net Income

-$15M-126.3% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+513.6%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$666M

Total Liabilities

$178M

Stockholders' Equity

$488M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$1M	+867.3%
Gross Profit	-$10M	-$2M	-409.8%
Operating Income	-$16M	-$22M	+28.4%
Net Income	-$15M	-$25M	+38.9%